Botulinum Neurotoxin Type A for the Treatment of Benign Prostatic Hyperplasia: Randomized Study Comparing Two Doses

Table 1

Baseline characteristics of patients treated with intraprostatic BoNT-A.

	BoNT-A 100 UI	BoNT-A 200 UI	P value
N	17	17
Age (yr)	66 ± 8.8	67 ± 10.0	0.59
IPSS	22.0 ± 6.4	22.0 ± 6.9	0.72
Qmax (mL/s)	8.6 ± 3.1	8.4 ± 3.1	0.87
PVR (mL)	131.8 ± 65.0	121.1 ± 73.7	0.88
Prostate volume (mL)	42.3 ± 18.5	43.1 ± 19.7	0.83
PSA (ng/dL)	3.9 ± 4.1	4.1 ± 2.7	0.86

IPSS: international prostatic symptom score, Q_max: maximum urinary flow rate, PVR: postvoid residual volume.